BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235),
BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide
. | May 6, 2023